BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15450337)

  • 1. Current concepts and review of alefacept in the treatment of psoriasis.
    Krueger GG
    Dermatol Clin; 2004 Oct; 22(4):407-26, viii. PubMed ID: 15450337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
    Ortonne JP; Khemis A; Koo JY; Choi J
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
    Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
    Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
    Ortonne JP; Prinz JC
    Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
    Ortonne JP
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.
    Krueger GG
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():17-24. PubMed ID: 12795771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
    Scheinfeld N
    J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
    Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
    J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
    Ellis CN; Krueger GG;
    N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remittive effects of intramuscular alefacept in psoriasis.
    Gordon KB; Langley RG
    J Drugs Dermatol; 2003 Dec; 2(6):624-8. PubMed ID: 14711140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical update on alefacept: consideration for use in patients with psoriasis.
    Gade JN
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
    Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term remission after 1 course of 12 weeks of alefacept therapy--a case report.
    Vitéz L; Heese E; Wozel G
    Dermatology; 2005; 211(2):165-6. PubMed ID: 16088168
    [No Abstract]   [Full Text] [Related]  

  • 15. Alefacept: an expert review concerning the treatment of psoriasis.
    Langley RG; Cherman AM; Gupta AK
    Expert Opin Pharmacother; 2005 Oct; 6(13):2327-33. PubMed ID: 16218892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alefacept: a review of the literature and practical guidelines for management.
    Hodak E; David M
    Dermatol Ther; 2004; 17(5):383-92. PubMed ID: 15379773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alefacept: a novel biologic in the treatment of psoriasis.
    Liu CM; McKenna JK; Krueger GG
    Drugs Today (Barc); 2004 Dec; 40(12):961-74. PubMed ID: 15645008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alefacept.
    Frampton J; Wagstaff A
    Am J Clin Dermatol; 2003; 4(4):277-86; discussion 287. PubMed ID: 12680805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.
    Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E;
    J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
    Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
    J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.